PT-141
PT-141 (Bremelanotide) (10mg)
$120USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.274
Reference number
10mg
Lyophilized vial
Melanocortin receptor agonist derived from Melanotan II. FDA-approved analog Vyleesi indicated for HSDD. Research analog for in vitro study.
Origin
PT-141 (Bremelanotide) was developed at the University of Arizona by Hadley, Hruby, and colleagues as a cyclic heptapeptide analog of alpha-MSH. It emerged from the Melanotan II research program when unexpected effects on sexual function were observed during tanning studies in the late 1990s.
Research Lineage
Palatin Technologies advanced PT-141 through clinical development, resulting in FDA approval of Vyleesi (bremelanotide) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Diamond et al. published Phase III clinical trial results. The research analog is used in melanocortin receptor binding studies and CNS pathway research.
Mechanism of Action
PT-141 is a non-selective melanocortin receptor agonist with preferential activity at MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors, its mechanism involves central nervous system activation rather than peripheral vasodilation. It does not require sexual stimulation to produce measurable neuroendocrine effects in preclinical models.
Structural Notes
Cyclic heptapeptide. Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Molecular weight: 1025.18 Da.
Key References
Diamond LE et al. J Sex Med. 2006;3(4):628-38.
Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.